|
|
|
| Effect of TACE Combined with Apatinib or Solafinib on Alpha-fetoprotein in Patients with Hepatocellular Carcinoma |
| CHEN Xiu-feng |
| Yixing Peoples Hospital of Jiangsu Province,214200 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with apatinib or Solafinib on alpha-fetoprotein (AFP) in patients with Hepatocellular Carcinoma (HCC). 【Methods】 A total of 60 patients with HCC admitted to our hospital from July 2015 to April 2019 were randomly divided into two groups. The solafinib group (n=30) was treated with TACE combined with solafinib, while the apatinib group was treated with TACE combined with apatinib. The clinical efficacy of the two groups was analyzed. 【Results】 There was no significant difference in objective remission rate between the apatinib group (56.67%) and the solafinil group (53.33%) (P>0.05).The levels of AFP, heat shock protein 90 α (Hsp90 α) and vascular endothelial growth factor (VEGF) between the two groups before treatment were not significantly different (P>0.05). After treatment, the levels of AFP,Hsp90 α and VEGF in the two groups were lower than those before treatment (P<0.05). However, there was no significant difference in the levels of AFP, Hsp90 α and VEGF between the apatinib group and the solafinil group after treatment (P>0.05). No patients had grade Ⅳ adverse reactions in both groups. The incidence of skin and mucous membrane reaction (73.33%) and hypertension (56.67%) in the apatinib group were higher than those in the solafinil group. The incidence of bone marrow suppression (46.67%) and gastrointestinal reaction (53.33%) of the apatinib group were not significantly different from those of the solafinil group (P>0.05). 【Conclusion】 After TACE, the efficacy of apatinib or solafinib in the treatment of HCC is similar showing that the expression of AFP,Hsp90α and VEGF was decreased, however, the safety of solafinib was relatively higher than that of apatinib.
|
|
Received: 05 September 2019
|
|
|
|
|
|
[1] 王丽森,余辉,程建中,等.TACE 和RFA对原发性肝癌的疗效及对细胞免疫、血清相关标志物水平的影响[J].癌症进展,2017,15(12):1460-1463.
[2] Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J].Cancer Biol Ther,2017, 18(6):433.
[3] 杨泽冉, 苏天昊, 尉建安,等. 肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌疗效评价[J].中国肿瘤临床, 2017, 44(17):880-885.
[4] 金鑫荔, 卢伟. TACE联合阿帕替尼治疗中晚期肝细胞癌[J].中国介入影像与治疗学, 2017, 14(4):200-204.
[5] 李磊, 钟敏钰, 宋海斌. 索拉非尼联合TACE治疗对肝癌患者血清相关细胞因子表达的影响[J].现代消化及介入诊疗, 2017, 22(4):482-484.
[6] 徐勤, 高珊, 缪继东,等. TACE联合阿帕替尼治疗中晚期原发性肝癌的临床疗效分析[J].西部医学, 2018,30(5):125-128.
[7] Kong Y, Lin S, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma[J].Oncotarget,2017, 8(62):105596-105605.
[8] 杨忠明, 李敬东, 余拥新,等. TACE联合索拉非尼治疗晚期肝癌的临床效果研究[J].中国现代普通外科进展, 2018, 21(6):433-436.
[9] 谢青云, 雷泽华, 高峰畏,等. 原发性肝癌TACE介入治疗前后血清AFP、AKP、 γ-GT水平的变化[J].昆明医科大学学报, 2018, 39(10):109-112.
[10] 宋继福, 宋超, 李春雷,等. 热休克蛋白90α及甲胎蛋白与肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝细胞癌疗效的相关性分析[J].肝脏, 2018,23(5):66-69.
[11] 刘亮, 刘劲松, 贺娟. 原发性肝癌患者TACE术后血清HIF-1α和VEGF水平变化[J].实用肝脏病杂志, 2017, 20(6):781-782. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(5): 783-785. |
|
|
|
|
2020, Vol. 37 
